No Data
Concept mining | Simgeglutide weight loss drug officially launched in China, multiple e-commerce platforms have gone online
The market has broad prospects
Investors Push Hybio Pharmaceutical (SZSE:300199) 4.1% Lower This Week, Company's Increasing Losses Might Be to Blame
hybio pharmaceutical (300199.SZ): On October 30th, Liraglutide injection ushered in a large-scale shipment with a total value of 0.103 billion yuan.
Gelonghui November 4th丨hybio pharmaceutical (300199.SZ) stated on the investor interaction platform that on October 30th, the company's Lirarutide Injection received a large-scale delivery, with a total value of 0.103 billion yuan, which was a commercial batch order announced by the company on November 3, 2023. In the future, the company will maintain a long-term exclusive cooperation relationship with Hikma according to the agreement, continue to advance subsequent order deliveries based on the sales market demand in the USA, and receive double-digit sales profit sharing. In addition to this order, the company will gradually issue subsequent orders based on the project progress. Please stay tuned for future order fulfillment.
Hanyu Pharmaceutical: Report for the third quarter of 2024
Hybio Pharmaceutical Gets China Approval for Type 2 Diabetes Injection
hybio pharmaceutical (300199.SZ): received a large prepayment of over 45 million yuan from Hikma yesterday.
On October 14, Gelonhui reported that hybio pharmaceutical (300199.SZ) announced that the cooperation progress of Liralutide preparations with Hikma in the usa market is smooth. Yesterday, Hikma has received a large prepayment of more than RMB 45 million from Hikma, and the company will orderly advance the supply chain guarantee work according to the agreement of both parties. In addition, the independently developed Liralutide preparations of the company obtained Tentative approval from the FDA in the usa in June this year and initiated the application for listing and sales to the FDA at the end of September and obtained approval for acceptance. Please pay attention to the company's public information on this matter.
Subdued Growth No Barrier To Hybio Pharmaceutical Co., Ltd. (SZSE:300199) With Shares Advancing 28%
